IMO we're past the hiccups stage already.
NTI is a microcap.
It can't do everything on its own.
The less distraction and diversion of resources from the most promising indication the better.
ASD has excellent efficacy and safety.
ASD has huge unmet need.
ASD doesn't have an approved treatment.
I'd be happer if NTI pursued only ASD until ASD is either partnered or approved.
By all means go off on a tangent later.
Chart - NTI, page-139
-
- There are more pages in this discussion • 1 more message in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
